Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
Schmitz A, Brøndum RF, Johnsen HE, Mellqvist UH, Waage A, Gimsing P, Op Bruinink DH, van der Velden V, van der Holt B, Hansson M, Andersen NF, Frølund UC, Helleberg C, Schjesvold FH, Ahlberg L, Gulbrandsen N, Andreasson B, Lauri B, Haukas E, Bødker JS, Roug AS, Bøgsted M, Severinsen MT, Gregersen H, Abildgaard N, Sonneveld P, Dybkær K. Schmitz A, et al. Among authors: van der velden v, van der holt b. BMC Cancer. 2022 Feb 5;22(1):147. doi: 10.1186/s12885-022-09184-1. BMC Cancer. 2022. PMID: 35123422 Free PMC article.
Minimal residual disease in leukaemia patients.
Szczepański T, Orfão A, van der Velden VH, San Miguel JF, van Dongen JJ. Szczepański T, et al. Among authors: van der velden vh, van dongen jj. Lancet Oncol. 2001 Jul;2(7):409-17. doi: 10.1016/s1470-2045(00)00418-6. Lancet Oncol. 2001. PMID: 11905735 Review.
Detection of minimal residual disease in acute leukemia.
van der Velden VH, Boeckx N, van Wering ER, van Dongen JJ. van der Velden VH, et al. Among authors: van dongen jj, van wering er. J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):146-54. J Biol Regul Homeost Agents. 2004. PMID: 15471219 Review.
Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol.
van der Velden VH, van der Sluijs-Geling A, Gibson BE, te Marvelde JG, Hoogeveen PG, Hop WC, Wheatley K, Bierings MB, Schuurhuis GJ, de Graaf SS, van Wering ER, van Dongen JJ. van der Velden VH, et al. Among authors: van dongen jj, van wering er, van der sluijs geling a. Leukemia. 2010 Sep;24(9):1599-606. doi: 10.1038/leu.2010.153. Epub 2010 Jul 29. Leukemia. 2010. PMID: 20668473
Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia.
Denys B, van der Sluijs-Gelling AJ, Homburg C, van der Schoot CE, de Haas V, Philippé J, Pieters R, van Dongen JJ, van der Velden VH. Denys B, et al. Among authors: van der velden vh, van dongen jj, van der schoot ce, van der sluijs gelling aj. Leukemia. 2013 Mar;27(3):635-41. doi: 10.1038/leu.2012.231. Epub 2012 Aug 16. Leukemia. 2013. PMID: 22945774
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.
Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S, van der Velden VHJ, Pérez-Morán JJ, Vidriales MB, García-Sanz R, Jimenez C, González M, Martínez-López J, Corral-Mateos A, Grigore GE, Fluxá R, Pontes R, Caetano J, Sedek L, Del Cañizo MC, Bladé J, Lahuerta JJ, Aguilar C, Bárez A, García-Mateo A, Labrador J, Leoz P, Aguilera-Sanz C, San-Miguel J, Mateos MV, Durie B, van Dongen JJM, Orfao A. Flores-Montero J, et al. Among authors: van dongen jjm, van der velden vhj. Leukemia. 2017 Oct;31(10):2094-2103. doi: 10.1038/leu.2017.29. Epub 2017 Jan 20. Leukemia. 2017. PMID: 28104919 Free PMC article.
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, Dozza L, van der Holt B, Zweegman S, Oliva S, van der Velden VHJ, Zamagni E, Palumbo GA, Patriarca F, Montefusco V, Galli M, Maisnar V, Gamberi B, Hansson M, Belotti A, Pour L, Ypma P, Grasso M, Croockewit A, Ballanti S, Offidani M, Vincelli ID, Zambello R, Liberati AM, Andersen NF, Broijl A, Troia R, Pascarella A, Benevolo G, Levin MD, Bos G, Ludwig H, Aquino S, Morelli AM, Wu KL, Boersma R, Hajek R, Durian M, von dem Borne PA, Caravita di Toritto T, Zander T, Driessen C, Specchia G, Waage A, Gimsing P, Mellqvist UH, van Marwijk Kooy M, Minnema M, Mandigers C, Cafro AM, Palmas A, Carvalho S, Spencer A, Boccadoro M, Sonneveld P. Cavo M, et al. Among authors: van marwijk kooy m, van der velden vhj, van der holt b. Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30. Lancet Haematol. 2020. PMID: 32359506 Clinical Trial.
Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network.
Hofste op Bruinink D, Oliva S, Rihova L, Schmitz A, Gilestro M, Te Marvelde J, Kralova R, Høholt H, Broijl A, Johnsen HE, Hajek R, Boccadoro M, Sonneveld P, Omedè P, Van der Velden VHJ. Hofste op Bruinink D, et al. Haematologica. 2020 Oct 5;106(5):1496-1499. doi: 10.3324/haematol.2020.267831. Haematologica. 2020. PMID: 33054135 Free PMC article. No abstract available.
252 results